

LIFE: IMPROVED CHEMISTRY SUCCESSFULLY TESTED IN SENSOR

Bergen, Norway, 4 February 2025: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce that chemistry with improved sensitivity has been successfully tested in Lifecare's CGM-sensor.

Reference is made to Lifecare's stock exchange announcement 14 January 2025, regarding up to fivefold improvement in sensor chemistry sensitivity, with a new generation of Lifecare's proprietary chemistry.

Lifecare's laboratory in Mainz, Germany, has now completed the first tests of the improved chemistry in implants similar to those used in the company's long-term studies. These implants have been subjected to laboratory testing. Similar to the initial and very promising tests of the chemistry in macro-test cells, the first analyses show promising responses after testing the chemistry in miniaturized sensors. This contributes to our expectation that the chemistry can lead to significantly improved sensor sensitivity. The actual function of the implants in-vitro will be subject to ongoing testing, after which the implants with improved sensor chemistry later will be subjected to long-term studies in-vivo.

The sensor sensitivity defines the potential to detect small changes of glucose levels and is an important performance parameter for CGM. The accuracy of CGM's is commonly referred to based on Mean Absolute Relative Difference (MARD), where a MARD lower than 10% indicates clinically acceptable accuracy. In Q2 2023, data from Lifecare's Clinical Development Study LFC-SEN-001 confirmed that our CGM system had achieved a MARD of 9,7%. The improved chemistry sensitivity can impact the MARD, however this is subject to further testing.

In a product perspective the most prominent benefit of enhanced sensor sensitivity is improvement of the sensor signal-to-noise ratio. This leads to improved data readings and enhanced sensor performance, as well as simplifying algorithms and data processing efficiency.

- Any validation of the improved chemistry sensitivity represents a confirmatory advance for our sensor technology. However, it is particularly promising that the improved chemistry sensitivity now has been subject to initial validation in a near-real-world test scenario. Lifecare's team of researchers and developers continuously strives for improved precision and quality in glucose monitoring to ensure better outcomes for patients with diabetes, says Joacim Holter, Lifecare CEO.



PRESS RELEASE
04 February 2025 07:00:00 CET

About us

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("**CGM**") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("**NTR**") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42